I got the bowel cancer screening kit in the mail. Should I actually bother?

Yes. The kit detects traces of blood in a stool sample — blood that isn't visible to the eye. Most positive results turn out not to be cancer (common causes include haemorrhoids, polyps, or benign inflammation), but a positive result means something is worth looking at. Bowel cancer is highly treatable when detected early; it is much harder to treat when found late. Using the kit takes a few minutes. A missed window can cost years.

My FOBT came back positive. Does that mean I have cancer?

No. A positive FOBT means blood was detected in your stool sample — it is not a diagnosis. The next step is a referral from your GP for a colonoscopy, which allows a gastroenterologist to look directly at the bowel. Most people who have a positive FOBT and then a colonoscopy are found to have a benign cause. The colonoscopy itself may also identify and remove precancerous polyps before they become a problem.

Bowel cancer screening and the July 2026 MBS change: what patients need to know

What just happened

On 1 July 2026, a structural change to Medicare’s billing framework came into effect for one specific and practically important pathway: colonoscopy after a positive bowel cancer screening FOBT. The new item — MBS 32219 — gives this specific indication its own dedicated billing code, separating it from item 32222, which previously covered multiple colonoscopy indications under a single descriptor.

The change is administrative. It does not alter who gets invited to screening, how the FOBT kit works, or the clinical threshold for follow-up colonoscopy. But administrative changes in healthcare pathways are not always trivial — and this one matters enough to understand, particularly if you are in the age group that Australia’s National Bowel Cancer Screening Program reaches by post.

Also effective from 1 July: a 2.6% general indexation applied to most Medicare items — a modest improvement the RACGP has noted does not keep pace with actual cost increases, given CPI of 4.2% over the prior year. But it is movement in the right direction.

The both-and

”This sounds like a billing technicality. Why does it matter to patients?”

It matters because the step between a positive FOBT result and an actual colonoscopy is where people fall out of the screening pathway. A positive screening test does not automatically produce a colonoscopy. It produces a GP letter, a patient conversation, a referral, an appointment with a gastroenterologist, and eventually the procedure itself. Each step is a potential drop-out point — from confusion, from cost anxiety, from the system losing track of the referral, from waiting lists that feel too long to bother with.

Cleaner billing pathways reduce friction at the provider end. When a gastroenterologist knows exactly which item to claim for a screening-indicated colonoscopy, versus a diagnostic colonoscopy for someone with symptoms, the administrative overhead is reduced. Data collection on this specific pathway becomes cleaner, meaning the program’s administrators can more clearly see where people are dropping out — and potentially act on it.

None of this happens immediately or automatically from a single MBS change. But the change is part of a broader effort to improve the coherence of the National Bowel Cancer Screening Program, which invites Australians across a wide age range to complete a free FOBT every two years. Bowel cancer is the second most common cause of cancer death in Australia. The program exists because catching it early dramatically changes outcomes.

”I’ve been ignoring my screening kit. Is that a problem?”

Frankly, yes. The kit is free, posted directly to you, and designed to be as low-barrier as possible. It tests for traces of blood in a stool sample — blood you would not be able to see. Most positive results turn out not to be cancer: haemorrhoids, benign polyps, and inflammatory causes are far more common explanations. But the value of the test is exactly that it catches the cases where something more serious is present before symptoms develop.

Bowel cancer is one of the more treatable cancers when found early. It is one of the harder ones to treat when found late. The interval between receiving a kit and using it — or not — can be consequential in a way that is genuinely difficult to recover from. If a kit is sitting unused in a drawer somewhere, the question worth asking is not whether it is convenient to do. The question is whether it is worth the few minutes of inconvenience to know.

2 cents

The July MBS change is not the news event of the week — it is a quiet structural improvement to how one important part of cancer care gets funded and tracked. But it is a useful prompt.

If you are in the age range the National Bowel Cancer Screening Program targets and you have not received a kit, check your eligibility at health.gov.au. If a kit arrived and you used it and got a positive result — and then stalled on the colonoscopy referral — that is the conversation to have with your GP this week, not at some unspecified future point. The new MBS item is not going to make your colonoscopy appointment happen automatically. But it does mean the path is a little better marked.

The broader lesson from these MBS changes is modest but worth stating: Medicare is a living document, and the items that fund your care change — sometimes in ways that affect what your GP can afford to offer you and how smoothly referrals are processed. Most patients never see this layer. The people who understand it a little are better positioned to advocate for themselves when things stall.

Verdict: yes — the MBS change is real and implemented; the screening context matters for patients in the relevant age group; and a positive FOBT result that has been sitting without follow-up is worth acting on now.

Sources cited

RACGP newsGP — 1 July MBS changes impacting general practice. https://www1.racgp.org.au/newsgp/professional/1-july-mbs-changes-impacting-general-practice
Australian Government — National Bowel Cancer Screening Program. https://www.health.gov.au/our-work/national-bowel-cancer-screening-program